3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
5
Neoplasms
3
Colorectal Neoplasms
3
Multiple Myeloma
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Myeloid
1
Sarcoma
1
Rhabdoid Tumor
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Polycythemia Vera
1
Parkinsonian Disorders
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
High Grade Neuroendocrine Neoplasms
1
Interventions
antineoplaston AS 2-1
4
antineoplaston A10
4
Cyclophosphamide
4
Cisplatin
4
Temozolomide
3
Radiotherapy
3
dactolisib
2
Vincristine
2
Filgrastim
2
Everolimus
2
Etoposide
2
Bevacizumab
2
spartalizumab
1
sargramostim
1
pasireotide
1
ganitumab
1
gallium Ga 68 dotatate
1
fosbretabulin
1
cixutumumab
1
belzutifan
1
aldesleukin
1
Topotecan
1
Thiotepa
1
TH 302
1
Sunitinib
1
Standard of Care
1
Pregabalin
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroectodermal Tumors, Primitive
×
Blood Specimen Collection
×
Clear all
NCT06861244
2026-04-23
PNOC031
University of California, San Francisco
Phase 2
Recruiting
70 enrolled